Immune Checkpoint Proteins
Stem Cell Research
Ion Channel Research
Protein kinase genes
Regeneron Pharmaceuticals Licenses OriGene TrueClone Collection
"We believe that full-length cDNAs isolated from cDNA libraries are the most reliable source of authentic coding regions for our critical applications." said Drew Murphy, Vice President of Target Discovery for Regeneron. "The OriGene True Clone collection has proven to be an excellent source of full-length human cDNAs for use in Regeneron's protein expression and target validation platforms."
Home Research Areas Immune Checkpoint Proteins |
Immune Oncology Checkpoint Proteins
Immune oncology (I-O) is the one of the most exciting research areas in biomedical science. Since the early discovery of CTLA4/CD80 and PD1/PDL1 interactions, scientists continue to discover novel ligands involve in T-cell activity modulations. The research results have been quickly translated in bedside benefit as a growing list of immune blockade drugs gaining FDA approval and perform miracles in cancer patients.
Read more [+]
Among the most promising approaches to activating therapeutic anti-tumor immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage.
It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are initiated by ligand–receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors.
Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse therapeutic opportunities.
OriGene offers a complete set of research tools for I-O research.
Click to view a complete product lists for that target.
Currently Approved Immune Checkpoint Inhibitors
|FDA approval date
||The current indications
|2011, Mar 25
||unresectable or metastatic melanoma
|2014, Sep 4
||metastatic melanoma; non-small cell lung cancer;head and neck cancer
|2014, Dec 22
||metastatic melanoma; non-small cell lung cancer; head and neck cancer
|2016, May 18
||lung cancer; urothelial cancer